Prediction of late normal tissue complications in RT treated gynaecological cancer patients: Potential of the γ-H2AX foci assay and association with chromosomal radiosensitivity

  • Authors:
    • Joke Werbrouck
    • Kim De Ruyck
    • Laurence Beels
    • Anne Vral
    • Marc Van Eijkeren
    • Wilfried De Neve
    • Hubert Thierens
  • View Affiliations

  • Published online on: February 1, 2010     https://doi.org/10.3892/or_00000671
  • Pages: 571-578
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In the present study, the γ-H2AX assay was investigated as a predictive test for the development of late normal tissue complications. Therefore, phosphorylated histone H2AX (γ-H2AX) foci were scored in peripheral blood T-lymphocytes of gynaecological radiotherapy patients, irradiated in vitro with a high dose rate (HDR) and a low dose rate (LDR) protocol. The G2 chromatid break assay was used to compare chromosomal radiation sensitivity with DNA double-strand-break (DSB) repair capacity. Late normal tissue reactions were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 scale. In our analyses, no differences in foci kinetics were found between the non to mild and moderate to severe patient groups after HDR irradiation. Furthermore, no relation was observed between the level of residual γ-H2AX foci and CTC score after LDR irradiation. On the contrary, the number of chromatid breaks was associated with late clinical radiation sensitivity. Comparison of G2 chromatid break assay data with the residual number of radiation-induced foci after LDR irradiation and repair times after HDR irradiation showed no relationship between the assays. From this study we can conclude that scoring of γ-H2AX foci after in vitro irradiation of isolated T-lymphocytes of patients is not predictive for late radiotoxicity. This applies as well to the assessment of the repair kinetics after an HDR dose as to the determination of the number of residual foci after a LDR dose.

Related Articles

Journal Cover

February 2010
Volume 23 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Werbrouck J, De Ruyck K, Beels L, Vral A, Van Eijkeren M, De Neve W and Thierens H: Prediction of late normal tissue complications in RT treated gynaecological cancer patients: Potential of the γ-H2AX foci assay and association with chromosomal radiosensitivity. Oncol Rep 23: 571-578, 2010
APA
Werbrouck, J., De Ruyck, K., Beels, L., Vral, A., Van Eijkeren, M., De Neve, W., & Thierens, H. (2010). Prediction of late normal tissue complications in RT treated gynaecological cancer patients: Potential of the γ-H2AX foci assay and association with chromosomal radiosensitivity. Oncology Reports, 23, 571-578. https://doi.org/10.3892/or_00000671
MLA
Werbrouck, J., De Ruyck, K., Beels, L., Vral, A., Van Eijkeren, M., De Neve, W., Thierens, H."Prediction of late normal tissue complications in RT treated gynaecological cancer patients: Potential of the γ-H2AX foci assay and association with chromosomal radiosensitivity". Oncology Reports 23.2 (2010): 571-578.
Chicago
Werbrouck, J., De Ruyck, K., Beels, L., Vral, A., Van Eijkeren, M., De Neve, W., Thierens, H."Prediction of late normal tissue complications in RT treated gynaecological cancer patients: Potential of the γ-H2AX foci assay and association with chromosomal radiosensitivity". Oncology Reports 23, no. 2 (2010): 571-578. https://doi.org/10.3892/or_00000671